Prospect Therapeutics Inc. has synthesized new substituted tricyclic derivatives acting as tyrosine-protein kinase JAK1 and non-receptor tyrosine-protein kinase TYK2 inhibitors.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has divulged new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an EGFR-targeting moiety via a linker.

Arcus Biosciences Inc. has reported piperidylurea compounds acting as Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists.

Pivot Therapeutics Inc. has patented RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors potentially useful for the treatment of cancer.

Triana Biomedicines Inc. has disclosed ALK tyrosine kinase receptor degradation inducers intended for use in the treatment of cancer.

Retex Pharmaceuticals Inc. has patented vasopressin V2 receptor antagonists potentially useful for the treatment of hyponatremia, cardiovascular disorders, autosomal dominant and autosomal recessive polycystic kidney.

Merck Sharp & Dohme LLC (MSD) has reported compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors designed for use in the treatment of cancer.

Biofront Therapeutics (Beijing) Co. Ltd. has prepared and tested cathepsin L (CTSL) inhibitors potentially useful for the treatment of acute respiratory distress syndrome (ARDS), cancer, diabetes, liver injury, viral infections and bone, inflammatory and renal disorders, among others.

Gan & Lee Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)- and/or SMARCA4-targeting moiety.

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein τ (PHF-τ; MAPT) aggregation inhibitors.